1 / 4
Tirzepatide is an investigational once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule.
Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion. It also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain harboring GLP-1 receptors to signal satiety.
Tirzepatide is a novel medication that is FDA approved for the treatment of type 2 diabetes mellitus. Given its potent weight loss properties, tirzepatide can be used off-label for obesity treatment. It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as semaglutide. It is currently implemented as a second-line diabetes medication, similar to GLP-1 medications, and given as a once-a-week subcutaneous injectable.
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which is FDA-approved for treating type 2 diabetes mellitus. It is important to note that tirzepatide is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, leading to significantly improved glycemic control in type 2 diabetics and significant weight reduction.
Current clinical data has demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1C levels. The SURPASS-5 clinical trial showed a -2.11% reduction in hemoglobin A1C levels at 5mg per week dosing, compared to -0.86% with placebo. At the highest dose of 15 mg per week, tirzepatide led to a -2.34% reduction in hemoglobin A1C. This was demonstrated over 40 weeks. A weight reduction of 5.4 kg was seen with 5mg of tirzepatide dosing, and a 10.5 kg reduction was seen with 15 mg dosing. This dose-dependent correlation with weight loss is similar to semaglutide, a common GLP-1 medication utilized for weight loss management.
| Products Name | Tirzepatide |
|---|---|
| CAS No. | 2023788-19-2 |
| Purity | 99% |
| Appearance | White Lyophilized powder |
| Logo printing | Available |
| Storage | Cool Dry Place |
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the natural GIP and GLP-1 hormones secreted after eating to stimulate insulin secretion, delay gastric emptying, and interact with satiety centers in the brain.
The FDA approved Tirzepatide in May 2022 for the treatment of type 2 diabetes mellitus as a second-line medication. Due to its potent weight loss effects, it is also used off-label for obesity management.
No. Tirzepatide is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis.
Tirzepatide is administered as a once-weekly subcutaneous injectable medication with incremental dose increases.
Over 40 weeks, tirzepatide demonstrated dose-dependent efficacy: a -2.11% reduction in hemoglobin A1C and 5.4 kg weight reduction at 5mg per week, compared to a -2.34% A1C reduction and 10.5 kg weight reduction at the 15mg weekly dose.
Tirzepatide has a CAS No. of 2023788-19-2, a purity of 99%, and appears as a white lyophilized powder. It should be stored in a cool, dry place.
